Secondary analysis of two phase I placebo-controlled dose-escalation trials in 84 healthy adults: neither ceftibuten nor ledaborbactam etzadroxil showed a concentration-related QTc effect; a >10 ms increase was excluded at and above expected therapeutic levels.
Secondary analysisn = 84
Darpo et al. No clinically relevant QTc prolongation with ceftibuten or ledaborbactam etzadroxil: concentration-QTc analyses from two phase I studies